Alcoholic Hepatitis Therapeutics Market Growth, Business Revenues, Qualitative Analysis and Forecast 2020 - 2030

Alcoholic Hepatitis Therapeutics Market: Introduction
According to the report, the global alcoholic hepatitis therapeutics market was valued at US$ 623.6 Mn in 2019 and is projected to expand at a CAGR of 6% from 2020 to 2030. Alcoholic hepatitis is a liver infection caused due to frequent and high consumption of alcohol. Fat that builds up in liver cells can lead to inflammation and scarring of the liver. The infection can be mild or severe. A patient may need a liver transplant if he does not receive treatment or stop consuming alcohol during the early stages. Different types of therapeutics are used in the treatment of alcoholic hepatitis, including corticosteroids, hemorrheologic agents, and anabolic steroids. The growth of the global alcoholic hepatitis therapeutics market can be ascribed to increase in prevalence of the alcoholic liver disease and rise in rate of consumption of alcohol across the globe.

Request Sample: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=12209

North America dominated the global alcoholic hepatitis therapeutics market in 2019. This trend is anticipated to continue during the forecast period. Highly structured healthcare industry, early new product adoption, high prevalence rate of alcoholic hepatitis, and presence of major players are estimated to drive the alcoholic hepatitis therapeutics market in North America. Asia Pacific is likely to be a highly lucrative region of the global alcoholic hepatitis therapeutics market. It is projected to expand at a fast-paced CAGR during the forecast period.
Increase in Prevalence of Alcoholic Liver Disease and Rise in Alcohol Consumption Rate to Drive Global Market
Increase in the number of patients afflicted with the alcoholic liver disease across the globe is a key factor driving the global alcoholic hepatitis therapeutics market. Around 88,000 people succumb to alcohol-related diseases annually, making alcohol the fourth leading preventable cause of death in the U.S. Rise in the rate of consumption of alcohol across the globe, especially in developed countries such as the U.S., is expected to boost the market in the near future. The use of alcohol varies throughout the world; the U.S. and Europe record the highest usage of alcohol. Around 67.3% of the population in the U.S. consumes alcohol in the U.S; of this, 7.4% meets the criteria for alcohol abuse.
Strong product pipeline is also anticipated to propel the global alcoholic hepatitis therapeutics market during the forecast period. For instance, Generon Pharmaceutical Technology (Shanghai) Co., Ltd. has an innovative product, F-652, in phase 2 of clinical trial.

Enquiry Before Buying: https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=12209

Corticosteroids Treatment to Dominate Alcoholic Hepatitis Therapeutics Market
Based on treatment, the global alcoholic hepatitis therapeutics market has been divided into corticosteroids, hemorrheologic agents, anabolic steroids, and others. The corticosteroids segment dominated the global alcoholic hepatitis therapeutics market in 2019. This trend is projected to continue during the forecast period. Corticosteroids are considered the first line of treatment in the management of alcoholic hepatitis. Thus, the segment accounts for significant share of the global alcoholic hepatitis therapeutics market.
Corticosteroids was followed by the hemorrheologic agents segment in terms of market share in 2019. Various clinical trials are being conducted to establish the efficacy of pentoxifylline in managing severe alcoholic hepatitis. This is augmenting the hemorrheologic agents segment.
Mild to be Highly Lucrative Application Area of Alcoholic Hepatitis Therapeutics Market
In terms of application, the global alcoholic hepatitis therapeutics market has been bifurcated into mild and severe/chronic. The mild segment accounted for a prominent share of the global alcoholic hepatitis therapeutics market in 2019, owing to rise in awareness about the ill effects of alcohol and early diagnosis of the disease.

Request Brochure: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=12209

Hospital Pharmacies to be Major Distribution Channel
In terms of distribution channel, the global alcoholic hepatitis therapeutics market has been classified into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment led the global alcoholic hepatitis therapeutics market in terms of revenue in 2019. The trend is expected to continue during the forecast period. Rapid increase in the number of hospitals and a wide range of services available in multispecialty hospitals are likely to boost the segment during the forecast period. Rise in the number of patients opting for retail pharmacies, due to a large number of product brands available at discounted prices at these pharmacies, is estimated to drive the retail pharmacies segment during the forecast period.
North America to Dominate Alcoholic Hepatitis Therapeutics Market
In terms of region, the global alcoholic hepatitis therapeutics market has been divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global alcoholic hepatitis therapeutics market in 2019. It was followed by Europe. Significant share of North America can be ascribed to the increase in the number of people with alcoholic hepatitis, new product launches, and presence of major players in the region. Furthermore, high consumption of alcohol, poor diet, and obesity are some of the common factors boosting the market in the region.

Request for covid19 Impact Analysis: https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=12209

The alcoholic hepatitis therapeutics market in Asia Pacific is anticipated to expand at a fast-paced CAGR from 2020 to 2030. This can be ascribed to the presence of developing economies with commercial hubs, expanding business organizations, growing awareness about alcoholic hepatitis, improving health care infrastructure, and rising investments by companies in their technical aspects.
Competition Landscape of Alcoholic Hepatitis Therapeutics Market
The global alcoholic hepatitis therapeutics market is fragmented in terms of number of players. Key players operating in the global market include Gilead Sciences, Inc., Sanofi, Generon Pharmaceutical Technology (Shanghai) Co., Ltd., Immuron Ltd., and Intercept Pharmaceuticals, Inc.

More Trending Reports by Transparency Market Research:

https://www.prnewswire.com/news-releases/pharmacovigilance-market-to-expand-at-cagr-of-8-8-during-forecast-period-observes-tmr-study-301480650.html

https://www.prnewswire.com/news-releases/contraceptives-market-to-gain-valuation-of-us-2-7-bn-by-2028--notes-study-by-tmr-301473001.html

Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/

About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

This release was published on openPR.